Affect Therapeutics
Using mobile technology to deliver the world's first evidence-based, substance-specific recovery program for methamphetamine and cocaine use disorder.
Employees
Enterprise value
$64—96m
Authorizing premium user...
Using mobile technology to deliver the world's first evidence-based, substance-specific recovery program for methamphetamine and cocaine use disorder.